论文部分内容阅读
Ｈａｅｕｓｌｅｒ等［１］在１９９０年报告了一个新的非甾体化合物来屈唑，对芳香化酶具有很强的抑制作用，导致卵巢分泌雌二醇（Ｅ２）减少。该药物在临床已用于他莫昔芬或其它抗雌激素药治疗失败的患有晚期乳腺癌的绝经后妇女，显示出优于其它二线激素治疗药甲地孕酮［２］?
Haeusler et al [1] reported in 1990 a new non-steroidal compound, farfloxacin, has a strong inhibitory effect on aromatase, leading to a decrease in ovarian secretion of estradiol (E2). This drug appears to be superior to other second-line hormone therapies, medroxyprogesterone acetate, in postmenopausal women with advanced breast cancer that have been clinically used for tamoxifen or other anti-estrogen therapies.